
Cost of severe neurological sequelae per year (€): 150 000 to 15 000
Cost of mild neurological sequelae per year (€): 120 000 to 4 500
MCADD prevalence at birth: 1/10 000 à 1/25 000
Cost (€) (tests/lab/year) of MCADD screening test: 3.38 (60 000) to 5.16 (30 000)
Risk of death after a metabolic crisis: 0.3 to 0.1
Effectiveness of MCADD screening to reduce the risk of metabolic crisis: 0.75 to 0.5
Risk of severe neurological sequelae: 0.05 to 0
% patients receiving L-carnitine supplementation until age 18 years: 0% to 100%
Risk of metabolic crisis: 0.75 to 0.67
Risk of mild neurological sequelae: 0.05 to 0
Utility score of a person not affected by MCADD: 1 to 0.9
Specificity of MCADD screening test: 1 to 0.9997
Utility score of a person with severe neurological sequelae: 0.45 to 0.76
Treatment cost of a metabolic crisis (€): 4 730 to 2 770
medical consultations/year until age 6 years in the absence of complications: 2 to 5
Utility score of a person with mild neurological sequelae: 0.89 to 0.92
-20 000
-10 000
0
10 000
20 000
Incremental cost-effectiveness ratio (€/QALY)